EBITDA or earnings before interest tax, depreciation and amortization rose 23.4% year-on-year to Rs 4,948.4 crore, compared to Rs 4,009 crore, while margins improved to 31.9%, compared to 29.3% in the same period last year.Sun Pharma has approved an interim dividend of Rs 11 per equity share of Re 1 each for the financial year 2025-2026. The company had previously announced on January 20, 2026 that the record date for determining shareholders eligible for the interim dividend has been set as February 5, 2026.
The interim dividend will be paid on or before February 16, 2026, the company said.
The company’s total costs fell by almost 9% in the third quarter. It reported a total expenditure of Rs 11,383 crore in Q3FY26 versus Rs 10,438 crore in the corresponding quarter of the previous fiscal.
American formulations
US formulation sales were $477 million, recording marginal growth of 0.6%. Continued momentum in innovative medicines helped offset the decline in the generics sector. The US market contributed approximately 27.5% to the total consolidated turnover. Through the first nine months, sales in the region amounted to $1,445 million.
Formulations for emerging markets
Formulation sales in emerging markets amounted to US$337 million, reflecting strong growth of 21.6% and accounting for 19.4% of total consolidated sales. During the first nine months, sales increased to US$960 million, an increase of 12.4% compared to the same period last year.
Formulations from the rest of the world
Formulation sales in the rest of the world markets amounted to US$296 million, up 14.5%, and contributed 17.1% of total consolidated sales. During the first nine months, sales amounted to $749 million, a growth of 15.8% compared to the corresponding period last year.
India formulations
Formulation sales in India stood at Rs 49,986 million, a growth of 16.2%. Formulations from India contributed 32.3% to total consolidated sales. For the nine-month period, sales stood at Rs 144,545 million, up 13.7% over the same period last year.
Sun Pharma retained its position as India’s largest pharmaceutical company, with market share increasing from 8.1% to 8.4%, according to the December 2025 Pharmarack MAT report. According to the July-October 2025 SMSRC report, Sun Pharma ranked No. 1 in prescriptions across 14 different physician categories. The company launched twelve new products this quarter, bringing the total number of launches to 26 so far this year.
R&D update
Sun Pharma’s research and development efforts span both its innovative and generic businesses, with continued investments aimed at strengthening its pipeline in multiple markets. The company’s innovative R&D pipeline currently includes five new entities in the clinical phase. In the US market, Sun Pharma has a broad product portfolio with approved ANDAs for 550 products, while 116 ANDA applications are pending US FDA approval, including 28 provisional approvals. During the quarter, the company filed two ANDAs and received approval for two others.
(Disclaimer: Recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of The Economic Times)
#Sun #Pharma #results #Cons #PAT #rises #YoY #crore #11share #interim #dividend #declared